Sitravatinib, a Tyrosine Kinase Inhibitor, Inhibits the Transport Function of ABCG2 and Restores Sensitivity to Chemotherapy-Resistant Cancer Cells in vitro-Reference-Cited by-同舟云学术

Sitravatinib, a Tyrosine Kinase Inhibitor, Inhibits the Transport Function of ABCG2 and Restores Sensitivity to Chemotherapy-Resistant Cancer Cells in vitro

Published:2020-05-12 Issue: Volume:10 Page:
ISSN:2234-943X
Container-title:Frontiers in Oncology
language:
Short-container-title:Front. Oncol.

Author:

Yang Yuqi,Ji Ning,Teng Qiu-Xu,Cai Chao-Yun,Wang Jing-Quan,Wu Zhuo-Xun,Lei Zi-Ning,Lusvarghi Sabrina,Ambudkar Suresh V.,Chen Zhe-Sheng

Funder

National Institutes of Health

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Reference49 articles.

1. Molecular mechanisms of drug resistance and its reversal in cancer;Kartal-Yandim;Crit Rev Biotechnol.,2016

2. ABC transporters in cancer: more than just drug efflux pumps;Fletcher;Nat Rev Cancer.,2010

3. Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies;Amiri-Kordestani;Drug Resist Updat,2012

4. Selonsertib;Ji;Cancer Lett.,2019

5. Complete characterization of the human ABC gene family;Dean;J Bioenerg Biomembr,2001

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Magnolol derivatives as specific and noncytotoxic inhibitors of breast cancer resistance protein (BCRP/ABCG2);Bioorganic Chemistry;2024-05

2. Polymeric nano-formulation of spectrum selective RTK inhibitor strengthens anti-cancer effects via immune remodeling by endoplasmic reticulum stress-modulating mitochondrial metabolism;Nano Today;2024-02

3. Signaling mechanisms of chemoresistance in breast cancer stem cells for therapeutics;Cancer Stem Cells and Signaling Pathways;2024

4. Emerging agents for the treatment of advanced or metastatic NSCLC without actionable genomic alterations with progression on first-line therapy;Expert Review of Anticancer Therapy;2023-07-24

5. The AKT inhibitor, MK-2206, attenuates ABCG2-mediated drug resistance in lung and colon cancer cells;Frontiers in Pharmacology;2023-07-13